Skip to main content

Table 2 Differences in quality of life trajectories between amyloid-positive and amyloid-negative SCD and MCI patients

From: A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

   EQ-5D utilities VAS
Unadjusted Model 1 Model 2 Model 3 Unadjusted Model 1 Model 2 Model 3
Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) Β (SE)
SCD positive 0.03 (0.02) 0.03 (0.02) 0.03 (0.02) 0.03 (0.02) 4.81 (2.02)* 4.57 (2.08)* 4.03 (2.05)* 4.06 (1.96)*
  Time * positive − 0.01 (0.004)* − 0.01 (0.004)* − 0.01 (0.004)* − 0.01 (0.004)* − 1.10 (0.45)* − 1.08 (0.45)* − 1.08 (0.45)* − 0.96 (0.45)*
MCI positive 0.10 (0.02)* 0.10 (0.02)* 0.09 (0.02)* 0.07 (0.21)* 7.68 (2.25)* 7.65 (2.32)* 6.01 (2.30)* 4.34 (2.32)
  Time * positive − 0.01 (0.004)* − 0.01 (0.004)* − 0.01 (0.004)* − 0.01 (0.004)* − 1.21 (0.44)* − 1.19 (0.44)* − 1.12 (0.44)* − 1.07 (0.44)*
  1. Model 1: adjusted for age and sex
  2. Model 2: additionally adjusted for comorbidity score, education, squared education (only for EQ-5D models in MCI patients) and EQ-5D scale (EQ-5D only)
  3. Model 3: additionally adjusted for GDS
  4. *p < 0.05
  5. Of note: main effect of amyloid status represents the average difference between amyloid-positive and amyloid-negative patients at baseline; interaction effect represents the difference in QoL over time between amyloid-positive and amyloid-negative patients
  6. SCD subjective cognitive decline, MCI mild cognitive impairment, Aβ positive amyloid positive, SE standard error, GDS Geriatric Depression Scale